

## CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
19 December 2024 (19.12.2024)

WIPO | PCT

(10) International Publication Number  
**WO 2024/255743 A9**



## (51) International Patent Classification:

C07D 237/22 (2006.01) C07D 405/14 (2006.01)  
C07D 401/12 (2006.01) A61K 31/501 (2006.01)  
C07D 405/06 (2006.01) A61P 25/00 (2006.01)  
C07D 405/12 (2006.01)

## (21) International Application Number:

PCT/CN2024/098527

## (22) International Filing Date:

12 June 2024 (12.06.2024)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

PCT/CN2023/099983

13 June 2023 (13.06.2023) CN

(71) Applicants: **ONO PHARMACEUTICAL CO., LTD.**  
[JP/JP]; 1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi,  
Osaka 541-8526 (JP). **VANDERBILT UNIVERSITY**  
[US/US]; 2201 West End Avenue, Nashville, Tennessee  
37240 (US).

(71) Applicant (for MG only): **WUXI APPTec (SHANGHAI)**  
**CO., LTD.** [CN/CN]; Building No. 1, 288 Fute Zhong  
Road, Pilot Free Trade Zone, Pudong New Area, Shanghai  
200131 (CN).

(72) Inventors: **LINDSLEY, Craig W.**; 9281 Wardley Park  
Lane, Brentwood, Tennessee 37027 (US). **ENGERS, Dar-**  
**ren W.**; 1744 Stillwater Circle, Brentwood, Tennessee  
37027 (US). **MURRAY, Jacob H.**; 60 Gale Terrace,  
Rochester, New York 14610 (US). **CHILDRESS, Eliza-**  
**beth S.**; 4656 Sterling Cross, Nashville, Tennessee 37211  
(US). **ABE, Masahito**; 427 Nichol Mill Lane Apt 352,  
Franklin, Tennessee 37067 (US). **HIROOKA, Yasuo**; c/o  
Ono Pharmaceutical Co., Ltd., 1-1, Sakurai 3-chome, Shi-  
mamoto-cho, Mishima-gun, Osaka 618-8585 (JP). **TANA-**  
**KA, Motoyuki**; c/o Ono Pharmaceutical Co., Ltd., 1-1,  
Sakurai 3-chome, Shimamoto-cho, Mishima-gun, Osaka  
618-8585 (JP). **KURATA, Haruto**; c/o Ono Pharmaceuti-  
cal Co., Ltd., 1-1, Sakurai 3-chome, Shimamoto-cho, Mishi-  
ma-gun, Osaka 618-8585 (JP). **GONDO, Naruhiro**; c/o

Ono Pharmaceutical Co., Ltd., 1-1, Sakurai 3-chome, Shi-  
mamoto-cho, Mishima-gun, Osaka 618-8585 (JP).

(74) Agent: **LIU, SHEN & ASSOCIATES**; 10th Floor, Build-  
ing 1, 10 Caihefang Road, Haidian District, Beijing 100080  
(CN).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report (Art. 21(3))
- with information concerning authorization of rectification  
of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))

## (48) Date of publication of this corrected version:


17 July 2025 (17.07.2025)

## (15) Information about Correction:

see Notice of 17 July 2025 (17.07.2025)



WO 2024/255743 A9

(54) Title: INHIBITORS OF TREK (TWIK RELATED K<sup>+</sup> CHANNELS) CHANNEL FUNCTION

(57) Abstract: Disclosed is a compound of formula (I), wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds and methods of using the compounds to prevent and/or treat disorders associated with dysregulation of TREK-1, TREK-2 or both TREK-1 and TREK-2 in a mammal.